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Introduction 
Patients who have recently been diagnosed as 
suffering from inflammatory bowel disease face two 
disturbing realities: firstly the true cause of the disease 
has not yet been defined and secondly the long term 
prognosis is unpredictable. The physician fighting the 
disease is often faced with a bewildering variety of drugs 
and preparations assembled in different regimens. Some 
of these regimens are still awaiting rigorous comparison 
by well conducted prospective trials in comparable 
cohorts of patients. This undesirable situation has 
resulted partly from the rapidity with which the main 
protagonists of the inflammatory response were 
characterised in recent years as a result of rapid 
expansion in the fields of immunology and cellular 
molecular biology. The exciting potential for targeting 
different steps in the inflammatory cascade with new 
drugs, many of which await clinical appraisal, suggests 
that medical treatment of inflammatory bowel disease is 
still in its infancy. This article therefore attempts to put 
in perspective the therapeutic regimens that have 
established themselves so far in this field, and to provide 
practical guidelines for their use in commonly 
encountered scenarios. 
Inflammatory bowel disease: from cause to cure 
In both ulcerative colitis (UC) and Crohn's disease 
(CD) unknown antigens appear to activate immune cells 
to release a number of cytokines and inflammatory 
mediators which then activate neighbouring 
macrophages and neutrophils in an uncontrolled fashion. 
These pro-inflammatory cytokines include the 
interleukins ILl, IL6 and IL8, granulocyte-monocyte 
colony stimlating factor (GMCSF) and tumour necrosis 
factor alpha (TNF alpha). The eicosanoid inflammatory 
mediators include leukotrienes (e.g. L TB4), 
prostaglandins (e.g. PG E2), platelet activating factor 
and thromboxane. Further entry of macrophages and 
neutrophils into the area is encouraged by adhesion 
molecules elaborated by the inflamed vascular 
endothelium and by strong chemo attraction induced by 
L TB4. Phagocytic leukocytes show enhanced inducible 
nitric oxide synthetase (iNOS) activity which results in 
enhanced liberation of nitric oxide (NO). NO is a 
vasodilator which maintains colonic mucosal integrity 
through its beneficial effects on the mesenteric 
circulation. However, excess NO may promote diarrhoea 
by stimulating the enteric nervous system to release 
vasoactive intestinal peptide (VIP)l and by combining 
with free radicles such as peroxide which have been 
shown to stimulate intestinal secretion2. Changes in 
mucosal blood flow and epithelial cell permeability are 
among the mechanisms causing diarrhoea. Each newly 
discovered inflammatory mediator has become a target 
for the design of new anti inflammatory agents which 
hold our hopes for the discovery of a drug which can 
maintain life long remission in this chronic disease. 
Over the last two decades, we have witnessed the 
introduction of a number of new preparations for the 
treatment of inflammatory bowel disease . Many of the 
these drugs have been evaluated in typical clinical 
scenarios and their efficacy in terms of induction and 
maintenance of remission has been compared by meW 
analysis of a large number of trials. This article will 
review the therapeutic options available to treat adults 
suffering from IBD, with particular reference to areas 
where consensus exists on specific regimens. 
Both UC and CD are often chronic diseases which 
vary in the extent of the disease and its response to 
treatment. Continuity of follow up, ideally in the same 
sub-speciality clinic, over a number of years must be· 
combined with careful serial endoscopic or radiological 
documentation of disease activity, the extent of bowel 
involvement, and its response to each therapeutic 
regimen. Since UC is a mucosal disease with a diffuse 
pattern, serial endoscopy is a useful guide to treatment. 
In contrast CD is best followed up by using a clinical 
non-endoscopic index such as the Crohn's disease 
activity index ( CDAI)3. 
Fighting IBD: Know your weapons 
UC can be treated with amino salicylates and 
glucocorticosteroids used singly or in combination, via 
topical and / or systemic routes. 
By inhibiting cycloxygenase, thromboxane 
synthetase and platelet activating factor synthetase 
aminosalicylates such as 5 - amino salicylic acid (5­
ASA) reduce inflammatory-mediating icosanoids 
generated from arachidonic acid. LTB4 and NO ate now 
established as inflammatory mediators in inflammatory 
bowel disease (IBD) and it is hoped that inhibitors of 
enzymes synthesising these chemicals may emerge as 
alternative anti inflammatories in the future. 5-ASA is 
available for topical use as retention enemas or 
suppositories or as an oral preparation. Orally 
administered 5-amino salicylic acid (5-ASA) is rapidly 
absorbed from the jejunum. Therefore oral formulations 
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use pH-dependent delivery systems that release the drug 
in higher concentrations in the distal small intestine and 
colon. These formulations, referred to as mesalazine (or 
mesalamine in the USA) employ a semipermeable 
membrane (Pentasa ®) or a resin-coat (Asacol ®) which 
delays release until intestinal pH has risen above 6.0. In 
addition pro-drugs are available such as olsalazine (two 
molecules of 5-ASA linked by an azo-bond), balsalazide 
(5-ASA linked to a peptide), and salazopyrine (5-ASA 
linked to sulfapyridine by an azo-bond). All three drugs 
release 5-ASA into the intestinal lumen after colonic 
bacteria digest the azo-bond. Less 5-ASA is released in 
the small intestine by pro-drugs than is the case with the 
-

mesalazine preparation. This minimises the risk of 
salicylate-induced renal damage, which includes an 
interstitial nephritis . Salazopyrine, originally introduced 
for the treatment of rheumatoid arthritis remains a 
popular anti inflammatory drug but carries added side 
effects such as hypersensitivity skin rashes, Heinz-body 
haemolytic anaemia and reversible male infertility, all of 
which are associated with the sulphonamide carrier. 
Alternatively, Glucocorticosteroids (GCS) represent a 
different approach to the inflammatory problem. They 
bind to the ubiquitous cellular glucocorticoid receptor 
which, when activated, travels to the nucleus where it 
influences DNA translation to produce potent anti 
inflammatory effects, which unfortunately extend to 
many tissues outside the bowel wall. The danger of side 
effects such as osteoporosis, cataracts and adrenal 
suppression limit their long term use. GCS can be 
administered intravenously e.g. hydrocortisone, orally 
e.g. prednisolene or rectally as foams e.g. hydrocortisone 
acetate 125 mg (Colifoam®) or Prednisolone 
metasulphobenzoate 20 mg (Predfoam®), as enemas 
e.g. prednisolone 20 mg (Predsol Enema®), or as 
suppositories e.g. prednisolone 5 mg (Predsol 
suppository®). Radioisotopic studies have shown a 
variable mucosal coverage by topical preparations. 
While suppositories and foams often coat the rectal 
mucosa, typical 100 ml enemas vary in their distribution, 
some coating only the lower sigmoid colon while others 
reach the ' splenic flexure. Positioning of the patient, 
bowel contents and motility may affect this distribution. 
Foams occupy a lower volume and are more likely to be 
retained than liquid enemas. In order to maximise 
compliance to enemas, the patient's motivation must be 
encouraged and any initial problems with self 
administration must be dealt with by close supervision. 
Since GCS are highly absorbed from inflamed bowel, 
systemic side effects (including adrenal suppression) can 
be minimised by administering budesonide 2mg in 100 
ml (Enterocort Enema®), a potent steroid which after 
being highly absorbed is largely cleared from the 
circulation by first pass hepatic metabolism to 
metabolites of low GCS potency. 
Patients who show an unsatisfactory response to 
intravenous steroids may require treatment with 
cyclosporin (Sandimmun®) 4 mg/kg iv as monotherapy4 
or combined with iv GCS which has a higher incidence 
of cumulative toxicity. Cyclosporin is a fungal 
metabolite which suppre~s cytotoxic T Iymphocytes 
with relative preservation of T suppressor cells and bone 
marrow, but with marked dose-related nephrotoxic 
potential. The intravenous preparation includes a 
hydrophobic vehicle which has been associated with 
anaphylaxis and with convulsions. The oral route may 
present problems with erratic absorption. Hypertension, 
hypomagnesaemia, hypertrichosis and a 
microangiopathic haemolytic anaemia can complicate 
the treatment. Absorption after oral dosing is less erratic 
if tacrolimus is used instead of cyclosporin but the scope 
of this drug is limited by more frequent neurotoxic and 
nephrotoxic side effects. Oral azathioprine (Imuran®) 
(1-3 mg /kg) is a purine antagonist anti metabolite with 
immunosuppressive effects which are more potent in CD 
than in Uc. It can be used as a sole agent or in 
combination with GCS as a steroid sparing drug (see 
below). Its commonest side effect is bone marrow 
suppression, predominantly thrombocytopenia or 
lymphopenia which is usually dose related and more 
likely to occur if angiotensin converting enzyme 
inhibitors are co-administered. Hepatotoxicity is usually 
reversible although life-threatening veno-occlusive liver 
disease may occur. Pancreatitis may also complicate use 
of azathioprine. Blood picture, serum amylase and liver 
function tests should therefore be regularly monitored. 
As with all immunosuppressive therapy there is an 
. increased risk of opportunistic infection and of 
neoplastic complications such as lymphoma, but many of 
these complications have been reported in renal 
transplant recipients receiving high doses of these drugs. 
Attacking ulcerative colitis: 
decide your strategy 
Modern medical management should not be based on 
open studies or isolated comparisons but on guidelines 
derived from meta analysis of reports by expert 
committees. Extensive reference is therefore made below 
to the practice guidelines published by the Practice 
Parameters Committee of the American College of 
Gastroenterology for the treatment of UC5.6. 
Colonoscopy is desirable to classify UC into distal 
(involvement only distal to splenic flexure) or extensive 
(involvement extending proximal to splenic flexure) 
colitis . Clinically the disease is classified as mild (less 
than four stools per day, with or without blood, no 
systemic toxicity, normal ESR) , moderate (more than 
four stools per day, minimal signs of toxicity), severe 
(more than six stools per day, toxicity such as fever, 
tachcardia, anaemia, raised ESR) 
Mild to moderate distal disease 
This category of patients may be treated with oral or 
topical treatment depending on patient preference. Oral 
treatment often takes longer to induce a remission than 
topical treatment but is frequently the patient's first 
choice. Combined oral and topical therapy is often 
recommended to achieve fast remission. Oral therapy 
consists of salazopyrine 4 - 6 g per day, mesalazine 2 to 
4 g per day or olsalazine 1.5 to 3 g per day, all in divided 
doses . The response is dose-related and many treatment 
failures are due to insufficient dosing. Regular full blood 
counts and tests of renal function are required. Caution 
should be exercized if there is mild renal impairment. 
Topical treatment includes mesalazine suppositories 500 
mg bd for proctitis or mesalazine enemas 2 - 4 g daily, 
while mesalazine 1 g enemas (available in Malta as 
Pentasa enemas®) are effective in maintammg 
remission7. Budesonide (2g/l 00 m\) enemas are also 
recommended as an alternative topical treatment, while 
hydrocortisone 10% foam was not found effective in 
maintaining remission. In general 5-ASA preparations 
are superior to topical steroids in maintaining remission 
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Mild to moderate extensive disease 
Here the disease is partly beyond the reach of enemas 
and its extent necessitates doses of oral 5-ASA 
preparations towards the upper limit of the dose ranges 
listed above. However, as the dose is titrated upwards 
side effects may occur. In addition a proportion of 
patients will not respond to maximum doses of 5-ASA. 
Such patients should be started on oral prednisolone 20 ­
60 mg per day tapering the dose downwards once 
clinical response is achieved. There are no official 
guidelines on tapering doses but dose reduction should 
proceed more gradually by 2.5 - 5 mg per week once 
lower doses are achieved. The tapering may take into 
account the steroid dose at which breakthrough of rectal 
bleeding or diarrhoea occurred during a previous 
exacerbation. Alternatively, a repeat colonoscopy may 
be performed while on low dose steroids (5 - 10 mg 
daily) to look for residual active disease before further 
tapering. Even if the mucosa appears normal, it is 
important to note that active cryptitis on biopsies is 
predictive of a recurrence if the steroid dose is lowered 
further. Distal residual disease may be healed by the 
addition of topical therapy while proximal incomplete 
healing may require the addition of azathioprine before 
steroid doses can be tapered or withdrawn. The 
therapeutic benefit of a given dose of azathioprine is not 
usually evident before three weeks and may not be 
complete before several months Besides its steroid­
sparing effect, azathioprine is also useful in maintaining 
remission although many patients achieve satisfactory 
prolongation- -of remission time if they tolerate and 
comply with sufficiently high doses of oral mes-alazine. 
Long term mesalazine is generally recommended in 
order to maintain remission. However, a study of 
patients who had been in remission for two years and 
who were randomised to long term mesalazine versus 
placebo did not show significant differences in relapse 
rates over several years between the two treatment 
arms8. 
Severe colitis 
Patients with clinically severe colitis and those with 
extensive colitis not responding to medical treatment 
should be admitted to hospital and treated with 
hydrocortisone 100 mg qds iv. Blood transfusion, 
intravenous fluids, antibiotics and total parenteral 
nutrition may also be required. Typically, 40% of 
patients with severe colitis will need surgery and it is 
important to identify these patients early. Approximately 
one third of these patients will have had one or more of 
these symptoms in the first-24 hours: more than 9 bowel 
actions per day, pulse above 100/min and maximum 
temperature above 38°C. By day 3, more than 8 stools 
per day, and a C-Reactive protein> 45 mg/l carry an 
85% chance of surgery9. Persistent colonic tenderness, 
early colonic dilatation or more than 3 distended small 
bowel loops are also ominous signs. The addition of 
intravenous cyclosporine 4 mg / kg /day reduces the 
need for urgent surgery,but many of these patients 
require surgery within the next six months under less 
dangerous conditions. 
A transverse colon with a diameter greater than 5 or 6 
cm with absent haustration on an abdominal radiograph 
associated with tachycardia and fever in a patient 
established on intravenous treatment ( toxic megacolon) 
requires emergency colectomy. When colonic dilation 
occurs at presentation, full intravenous treatment, 
correction of hypokalaemia and avoidance of opiates and 
anticholinergics may allow sufficient improvement after 
24 hours to avoid emergency colectomy. Medical 
management of severe colitis must also include vigilance 
for two complications that require emergency surgery, 
namely accelerated colonic bleeding and colonic 
perforation without preceding toxic dilation. 
Cancer surveillance: getting them soon enough 
When compared to non-coli tics, colitis-associated 
cancer occurs at an earlier age, is often mUltiple and 
frequently lacks the polyp-cancer sequence. Onset of 
colitis in childhood and a long period of continuous 
disease increase the risk of cancer in a time-dependent 
fashion (typically 7% risk at 20 years and 16% risk at 30 
years) 10. This has prompted many clinicians to 
recommend prophylactic colectomy in the past. 
Whereas many of these patients with a long duration 
of active disease extending beyond the rectosigmoid area 
underwent prophylactic colectomy in the past, most 
clinicians will now only consider this operation if 
persistent dysplasia is demonstrated in one or more 
mUltiple biopsies (taken at 10 cm intervals) during 
surveillance colonoscopies. Surveillance should start 
after 10 years of disease activity and should be repeated 
every 1 -3 years if no dysplasia is found. A finding of 
low grade dysplasia should be confirmed by repeating 
colonoscopy after a few weeks and then at six -monthly 
intervals until it disappears or high grade dysplasia is 
found, whereupon prophylactic colectomy is 
recommended. A 19% incidence of cancer was found in 
colons resected from UC patients shortly after their 
colonoscopy showed low grade dysplasia, while the five­
year predictive value of low grade dysplasia for cancer 
or for high grade dysplasia is as high as 54%. Colectomy 
should therefore be considered in all patients with 
persistent low grade dysplasia. 
The future in UC: feeding the colonocyte? 
Colonic mucosal cells derive 80% of their energy 
requirement from luminal short chain fatty acids 
(SCFA), mostly butyrate, produced by anaerobic 
bacterial fermentation of undigested dietary 
carbohydrates, mainly fibre polysaccharides 11 • Absence 
of luminal SCFA is thought to be the cause of "diversion 
colitis" in segments of colon which have been surgically 
isolated from the faecal stream. Reduced beta oxidation 
of butyrate by the colonic epithelial cells, with 
consequent energy deficiency, may promote mucosal 
cell death in uc. Several trials of SCFA enemas in UC 
have yielded disappointing results. Initial studies have 
shown that dietary fibre administered as Plantago Ovata 
seeds may be as effective as mesalazine in preventing 
relapse in ulcerative colitis l2 . By maintaining an acid 
pH in the colonic lumen, fermented fibre promotes the 
predominance of acidogenic bacteria over putrefactive 
bacteria. The latter digest protein to produce ammonia 
and sulphur-containing compounds which, by acting as 
reducing agents l 3, may impair colonocyte nutrition. 
Regimens that include dietary fibre which, while 
resisting enteric enzyme digestion are highly fermentable 
to butyrate in the colon, are likely to be scrutinised in the 
ne){t few years for their ability to maintain remission in 
UC. 
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Attacking Crohn's disease: 
be prepared to intensify treatment 
The presence of many sUbtypes of CD (colonic, 
ileocolonic, fistulating, stenotic) and the poor 
correlation of endoscopic appearance with disease 
activity for which there is no scientifically based index 
have prevented the definition of clear therapeutic 
endpoints. In comparison with UC many drug regimens 
used in CD have not been rigorously compared. 
Mild disease 
-
These patients are able to eat without developing signs 
of transmural inflammation such as fever, abdominal 
mass or tenderness. Sulphasalazine 3-6g/day was shown 
to induce remission in mild colonic and ileo-colonic 
disease by the National Cooperative Crohn's Disease 
(placebo-controlled) Study (NCCDS)14 and other 
studies, but only in some studies in ileal Crohn's. This 
may be due to insufficient splitting of azo-bonds in the 
ileum where the bacterial load is usually low. The pH­
dependent release preparation mesalazine (Pentasa®) 
induced remission in both ileal and colonic disease at a 
dose of 4g/day in a dose dependent fashion 15 and 
maintained remission at a dose of 3g/day as long as 
treatment was started within 3 months of remission. The 
efficacy of mesalazine in preventing inflammation in the 
neo-terminal ileum after resection of the terminal ileum 
and ileocaecal valve has not been adequately studied. 
Moderate disease 
~ These patients have often failed ·to respond to 5 ASA 
and have signs of transmural inflammation or anaemia. 
Patients tolerating oral medication should receive 0.5 ­
0.75 mg /kg prednisolone per day. This regimen induced 
remission in 47% and improvement in 60 % of patients 
at 16 weeks in the NCCDS. Dose tapering should 
commence once clinical remission occurs and need not 
wait for endoscopic improvement which often lags 
behind transmural healing. Treatment with Enterocort ® 
capsules (controlled release oral budesonide) 9 mg 
daily can be expected to induce remission in 52 - 60% 
of patients at 8 weeks and 62% of patients at 16 weeks 16. 
50 - 80 % of the drug is absorbed in the ileum and right 
colon, the bioavailability remaining unaltered after 
feeding. The preparation has a high solubility, a high 
affinity for steroid receptors, a high hepatic first-pass 
metabolism and a high potency, 9 mg of oral 
Enterocort® being equivalent to 40 mg of oral 
prednisolone. 
Patients who respond poorly or partially to steroids 
should also receive azathioprine starting at 0.5 - 1.5 mg/ 
kg and increasing to 2 to 2.5 mg/kg. In addition to its 
steroid-sparing effect, azathioprine prolongs remission 
and has specific healing effects on patients with fistulous 
disease. When allergic reactions limit the use of purine 
antagonists, methotrexate 25 mg i.m. weekly for 12 
weeks followed by 12.5 mg i.m. weekly may permit 
steroid tapering, but the potential for causing pulmonary 
or liver fibrosis and bone marrow suppression make 
methotrexate a less popular drug. 
Antibiotics are advocated in CD complicated by 
chronic suppuration such as abscess, sinus or fistula and 
in patients where intestinal strictures may cause 
prolonged contact with high counts of abnormal bacterial 
flora. The potential antigenic role of bacteria has been 
suggested by the protective effect of diverting the 
faecal stream (e.g. by the protective effects of loop 
ileostomy on the neo-terminal ileum after terminal ileal 
resection. Antibiotics include oral metronidazole 20 mg/ 
kg/day, reducing to lOmg/kg/day during remission, 
ciprofloxacin 1 g/day and clarithromycin, the latter being 
chosen in some studies because of its activity against 
Mycobacterium Paratuberculosis which has been 
implicated in the aetiology of CD. Elemental diets may 
also be added to limit antigenic stimulation by protein 
and to help reverse malnutrition. Total parenteral 
nutrition, often combined with Octreotide 50 ug s.c. 8 
hourly is useful when high output fistulae co-exist. 
Severe disease 
These patients are treated with intravenous steroids 
and all the supportive therapy listed under severe UC 
above. In addition, intestinal obstruction may require 
nasogastric suction and total parenteral nutrition until 
adhesive or fibrostenotic disease resolves. Abscesses 
may require surgical drainage. 
Maintaining remission 
Steroid doses below 8 mg per day are generally 
ineffective in maintaining a steroid induced remission 
but useful steroid sparing effects are to be expected by 
adding azathioprine 2.5 mg/kg /day. The early addition 
of oral mesalazine at doses above 3 grams per day is 
helpful in prolonging remission. 
The future in CD: harnessing the 
immune response? 
A number of research drugs have been shown to 
reduce activity in CD. For example, an alternative to the 
old methods of antigen reduction and immuno­
modulation is the exciting method of specific cytokine 
modulation. The most promising in early placebo­
controlled trials are the TNF-alpha blocking agents. 
These include chimeric (75% human, 25% mouse) and 
humanised antibodies against TNF-alpha which have 
been administered as single or multiple iv infusions in 
treatment-resistant CD patients. The anti-inflammatory 
cytokine 1 L-lO which decreases macrophage secretion 
of pro inflammatory cytokines such as IL 1 is still under 
trial. Going back to immunomodulation, we now have 
the possibility of targeting CD4 cells using anti-CD4 
monoclonal antibodies which have been shown to reduce 
populations of circulating CD4 cells, as well as reduced 
antigen presentation. Another logistic approach is to 
interfere with leukocyte recruitment to the site of 
inflammation by blocking strong adhesion molecules 
such as intercellular adhesion molecule 1 (lCAM-l). 
This has been achieved using an anti sense nucleotide 
with clinical responses in steroid dependent CD patients. 
Conclusion 
The impressive array of inflammatory mechanisms 
unearthed by research into the pathogenesis of 
inflammatory bowel disease makes it difficult for 
scientists to know where best to intercept the 
inflammatory cascade. It is not yet clear whether certain 
inflammatory events occur in tandem or in quick 
---
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succession. It is hoped that the early triggers of 
inflammation will prove to be amenable to suppression 
by new agents so that drugs that prevent remission will 
be used less commonly than those which prevent relapse. 
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